Skip to content

Avalo Therapeutics AVTX Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Xencor logo
XencorXNCR
$36.82M-2.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$12.04M-13.5%
Absci Corporation logo
Absci CorporationABSI
$2.63M-29.2%
Immunome logo
ImmunomeIMNM
$2.83M-32.1%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
11.1%+0.1pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$41.74M-10.7%

Other financials

Income statement

See full
Revenue$59.0K-69.3%
Gross profit$963.0K+8,855%
Operating income-$20.9M-42.5%
Net income-$19.6M-49.3%
EPS (diluted)-$0.98+21.6%

Balance sheet

See full
Cash & equivalents$25.3M-79.8%
Total debt$328.0K-59.1%
Total equity$68.3M-44.3%
Total assets$99.9M-27.9%

Cash flow

See full
Operating cash flow-$17.7M-87.1%
CapEx-
Free cash flow-$15.0M-444%

Valuation

See full
Market cap$954.59M+1,800%
Enterprise value$929.6M-1,353%
P/S1,909.2×+1,868×

Profitability

See full
Gross margin182%+176pp
Operating margin-15,536.1%-17,275pp
Net margin-7,965.8%-10,750pp
FCF margin-11,123.8%-13,374pp

Returns & leverage

See full
Return on equity-88.8%
Debt / equity0.0×
Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Avalo Therapeutics’s 10-Q, filed November 9, 2020, on SEC EDGAR. View the filing →

Questions, answered.

What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.